Drug Profile


Alternative Names: 7-thia-8-oxoguanosine; 7T80G; ANA-245; ICN-10146; ICN25; Immunosine; Immusine; KN 25; N10146; N12143; N14316; NARI-10146; Thiaoxoguanosine

Latest Information Update: 18 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis; Valeant Pharmaceuticals International
  • Developer Anadys Pharmaceuticals
  • Class Antineoplastics; Antivirals; Immunotherapies; Purine nucleosides; Small molecules
  • Mechanism of Action Interferon alpha stimulants; Natural killer cell stimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cancer; Hepatitis C

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 04 Nov 2004 Data presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2004) have been added to the adverse events , and Viral Infections pharmacodynamics and therapeutic trials sections
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top